Single-dose therapy of gonococcal ophthalmia neonatorum with ceftriaxone. 1986

M Laga, and W Naamara, and R C Brunham, and L J D'Costa, and H Nsanze, and P Piot, and D Kunimoto, and J O Ndinya-Achola, and L Slaney, and A R Ronald

We conducted a randomized clinical trial comparing a single intramuscular dose of 125 mg of ceftriaxone with a single intramuscular dose of 75 mg of kanamycin followed by topical gentamicin for seven days, and with a single intramuscular dose of 75 mg of kanamycin followed by topical tetracycline for seven days, in the treatment of gonococcal ophthalmia neonatorum in Nairobi, Kenya. Of 122 newborns with culture-proved gonococcal ophthalmia neonatorum, 105 returned for follow-up. Sixty-one infants (54 percent) received ceftriaxone, 32 received kanamycin plus topical gentamicin, and 29 received kanamycin plus topical tetracycline. Sixty-six (54 percent) of the Neisseria gonorrhoeae isolates were penicillinase producing. All 55 newborns who received ceftriaxone and returned for follow-up were clinically and microbiologically cured. One of 26 returning newborns who received kanamycin plus tetracycline and 2 of 24 returning newborns who received kanamycin plus gentamicin had persistent or recurrent gonococcal conjunctivitis. Ceftriaxone also eradicated oropharyngeal gonococcal infection in 18 newborns, whereas oropharyngeal infection persisted in 2 of 8 newborns who had received kanamycin (P not significant). We conclude that 125 mg of ceftriaxone as a single intramuscular dose is very effective therapy for gonococcal ophthalmia neonatorum, with marked efficacy against extraocular infection and without the need for concomitant topical antimicrobial therapy.

UI MeSH Term Description Entries
D007231 Infant, Newborn An infant during the first 28 days after birth. Neonate,Newborns,Infants, Newborn,Neonates,Newborn,Newborn Infant,Newborn Infants
D007273 Injections, Intramuscular Forceful administration into a muscle of liquid medication, nutrient, or other fluid through a hollow needle piercing the muscle and any tissue covering it. Intramuscular Injections,Injection, Intramuscular,Intramuscular Injection
D007612 Kanamycin Antibiotic complex produced by Streptomyces kanamyceticus from Japanese soil. Comprises 3 components: kanamycin A, the major component, and kanamycins B and C, the minor components. Kanamycin A,Kanamycin Sulfate,Kantrex
D009344 Neisseria gonorrhoeae A species of gram-negative, aerobic bacteria primarily found in purulent venereal discharges. It is the causative agent of GONORRHEA. Diplococcus gonorrhoeae,Gonococcus,Gonococcus neisseri,Merismopedia gonorrhoeae,Micrococcus der gonorrhoe,Micrococcus gonococcus,Micrococcus gonorrhoeae
D009878 Ophthalmia Neonatorum Acute conjunctival inflammation in the newborn, usually caused by maternal gonococcal infection. The causative agent is NEISSERIA GONORRHOEAE. The baby's eyes are contaminated during passage through the birth canal.
D011897 Random Allocation A process involving chance used in therapeutic trials or other research endeavor for allocating experimental subjects, human or animal, between treatment and control groups, or among treatment groups. It may also apply to experiments on inanimate objects. Randomization,Allocation, Random
D002443 Ceftriaxone A broad-spectrum cephalosporin antibiotic and cefotaxime derivative with a very long half-life and high penetrability to meninges, eyes and inner ears. Benaxona,Cefatriaxone,Cefaxona,Ceftrex,Ceftriaxon,Ceftriaxon Curamed,Ceftriaxon Hexal,Ceftriaxona Andreu,Ceftriaxona LDP Torlan,Ceftriaxone Irex,Ceftriaxone Sodium,Ceftriaxone Sodium, Anhydrous,Ceftriaxone, Disodium Salt,Ceftriaxone, Disodium Salt, Hemiheptahydrate,Lendacin,Longacef,Longaceph,Ro 13-9904,Ro-13-9904,Ro13-9904,Rocefalin,Rocefin,Rocephin,Rocephine,Tacex,Terbac,Anhydrous Ceftriaxone Sodium,Ro 13 9904,Ro 139904,Ro13 9904,Ro139904
D002986 Clinical Trials as Topic Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries. Clinical Trial as Topic
D004352 Drug Resistance, Microbial The ability of microorganisms, especially bacteria, to resist or to become tolerant to chemotherapeutic agents, antimicrobial agents, or antibiotics. This resistance may be acquired through gene mutation or foreign DNA in transmissible plasmids (R FACTORS). Antibiotic Resistance,Antibiotic Resistance, Microbial,Antimicrobial Resistance, Drug,Antimicrobial Drug Resistance,Antimicrobial Drug Resistances,Antimicrobial Resistances, Drug,Drug Antimicrobial Resistance,Drug Antimicrobial Resistances,Drug Resistances, Microbial,Resistance, Antibiotic,Resistance, Drug Antimicrobial,Resistances, Drug Antimicrobial
D005500 Follow-Up Studies Studies in which individuals or populations are followed to assess the outcome of exposures, procedures, or effects of a characteristic, e.g., occurrence of disease. Followup Studies,Follow Up Studies,Follow-Up Study,Followup Study,Studies, Follow-Up,Studies, Followup,Study, Follow-Up,Study, Followup

Related Publications

M Laga, and W Naamara, and R C Brunham, and L J D'Costa, and H Nsanze, and P Piot, and D Kunimoto, and J O Ndinya-Achola, and L Slaney, and A R Ronald
January 1986, Sexually transmitted diseases,
M Laga, and W Naamara, and R C Brunham, and L J D'Costa, and H Nsanze, and P Piot, and D Kunimoto, and J O Ndinya-Achola, and L Slaney, and A R Ronald
December 1984, Lancet (London, England),
M Laga, and W Naamara, and R C Brunham, and L J D'Costa, and H Nsanze, and P Piot, and D Kunimoto, and J O Ndinya-Achola, and L Slaney, and A R Ronald
July 1988, The British journal of ophthalmology,
M Laga, and W Naamara, and R C Brunham, and L J D'Costa, and H Nsanze, and P Piot, and D Kunimoto, and J O Ndinya-Achola, and L Slaney, and A R Ronald
June 1987, The New England journal of medicine,
M Laga, and W Naamara, and R C Brunham, and L J D'Costa, and H Nsanze, and P Piot, and D Kunimoto, and J O Ndinya-Achola, and L Slaney, and A R Ronald
January 1987, South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde,
M Laga, and W Naamara, and R C Brunham, and L J D'Costa, and H Nsanze, and P Piot, and D Kunimoto, and J O Ndinya-Achola, and L Slaney, and A R Ronald
January 1988, Sexually transmitted diseases,
M Laga, and W Naamara, and R C Brunham, and L J D'Costa, and H Nsanze, and P Piot, and D Kunimoto, and J O Ndinya-Achola, and L Slaney, and A R Ronald
December 2000, Indian pediatrics,
M Laga, and W Naamara, and R C Brunham, and L J D'Costa, and H Nsanze, and P Piot, and D Kunimoto, and J O Ndinya-Achola, and L Slaney, and A R Ronald
November 1986, The New England journal of medicine,
M Laga, and W Naamara, and R C Brunham, and L J D'Costa, and H Nsanze, and P Piot, and D Kunimoto, and J O Ndinya-Achola, and L Slaney, and A R Ronald
January 1949, Eye, ear, nose & throat monthly,
M Laga, and W Naamara, and R C Brunham, and L J D'Costa, and H Nsanze, and P Piot, and D Kunimoto, and J O Ndinya-Achola, and L Slaney, and A R Ronald
April 2021, Journal francais d'ophtalmologie,
Copied contents to your clipboard!